GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billion
GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includes an upfront payment of $1.2 billion and milestone payments. Efimosfermin, targeting steatotic liver disease and MASH, is expected to launch in 2029, with (...)
Site référencé: The Economic Times
The Economic Times
Berkshire endorses Japanese trading houses, could hold them 'forever'
3/05/2025
Buffett says US shouldn't use "trade as a weapon" as Trump has done with tariffs
3/05/2025
Buffett takes the stage at Berkshire Hathaway meeting
3/05/2025
DMart Q4 results : Standalone PAT jumps 2% YoY, revenue surges 17%
3/05/2025
Berkshire shareholders head to Buffett's 60th annual meeting, economy top of mind
3/05/2025
Concurrent Gainers : 4 stocks that gain for 5 days in a row
3/05/2025
